Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: Pharmacokinetic and pharmacodynamic effects

British Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2005, Pages 346-354

  Chaikin, P ^a   Gillen, M S ^b   Malik, M ^c   Pentikis, H ^d   Rhodes, G R ^e   Roberts, D J ^f  

^a Kyowa Pharmaceutical Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d ICON Development Solutions   (United States)

^e GILEAD SCIENCES   (United States)

^f Almirall Prodesfarma SA ^*  (Spain)

Author keywords

Ebastine; Ketoconazole; Loratadine; Pharmacodynamics; Pharmacokinetics; QTc interval

Indexed keywords

CAREBASTINE; DESLORATADINE; EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LORATADINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRY SKIN; DYSPNEA; ELECTROCARDIOGRAM; FIRST PASS EFFECT; HEADACHE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; BUTYROPHENONES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; HEART RATE; HISTAMINE H1 ANTAGONISTS; HUMANS; KETOCONAZOLE; LORATADINE; MALE; PIPERIDINES;

EID: 15244344403     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02348.x     Document Type: Article

References (30)

1. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
2. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation, implications for drug approval and labelling. Drug Safety 2001; 2: 323-51.
3. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-6.
4. Woosley RL. Cardiac actions of antihistamines. Ann Rev Phamacol Toxicol 1996; 36: 233-52.
5. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-Ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
6. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-70.
7. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001; 52: 201-4.
8. Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand 1920; 53: 469-86.
9. Malik M. Problems of heart rate correction in the assessment of drug induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12: 411-20.
10. Malik M. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2002; 54: 682-3.
11. Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998; 26: 566-71.
12. Yumibe N, Huie K, Chen KJ, Clement RP, Cayen MN. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistamine drug loratadine. Int Arch Allergy Immunol 1995; 107: 420.
13. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MM, Affrime MB. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50: 581-9.
14. Kawataki M, Kashima T, Toda H, Tanaka H. Relation between QT interval and heart rate. Applications and limitations of Bazett's formula. J Electrocardiol 1984; 17: 371-5.
15. Yoshinaga M, Tomari T, Aihoshi S, Kawashita T, Nishi J, Tanaka Y, Takezaki T, Kono Y, Yuasa Y, Nakamura M, Nomura Y, Oku S, Haraguchi T, Miyata K. Exponential correction of QT interval to minimize the effect of the heart rate in children. Jpn Circ J 1993; 57: 102-8.
16. Simonson E, Cady LD, Woodbury M. The normal Q-T interval. Am Heart J 1962; 63: 747-53.
17. Hodges M. Rate correction of the QT interval. Card Electrophysiol Rev 1997; 3: 360-3.
18. Boudolas H, Geleris P, Lewis RP, Rittgers SE. Linear relationship between electrical systole, mechanical systole, and heart rate. Chest 1981; 80: 613-7.
19. Mayeda I. On the time relation between the systolic duration of the heart and the pulse rate. Acta Scholae Med University Imp Kioto 1934; 17: 53-5.
20. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relationship between QT and RR intervals is highly individual among healthy subjects - implications for heart rate correction of the QT interval. Heart 2002; 87: 220-8.
21. Batchvarov V, Ghuran A, Smetana P, Hnatkova K, Harris M, Dilaveris P, Camm AJ, Malik M. The QT/RR relationship in healthy subjects exhibits substantial intersubject variability and a high intrasubject stability. Am J Physiol Heart Physiol 2002; 282: H2356-63.
22. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. London: European Medicines Agency; 1997; http://wvwv.emea.eu.int.
23. Advanced Bioanalytical Services, Inc. Analytical Report no. 96 APKB01.RPR. Ithaca, NY: Advanced Bioanalytical Services; 1996.
24. MDS Pharma Services. Analytical Report no. 970278/GTR (SOP no. 2369-02). Montreal (Saint-Laurent), Quebec: MDS Pharma Services (previously Phoenix International Life. Sciences, Inc.) 1997.
25. Moss AJ, Morganroth J. Cardiac effects of ebastine and other antihistamines in humans. Drug Safety 1999; 21(Suppl 1): 69-80.
26. Brenton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413-8.
27. Rodriguez I, Kilborne MJ, Liu X-K, Pezzullo JC, Woosley RL. Drug induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-6.
28. Data on file Almirall Prodesfarma. Final study report M/EBS/25, 2002.
29. Package insert, Claritin® Physician's Desk Reference, Edition 57 2003: 3018-20. Thomson PDR, Montvale, NJ, USA.
30. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin C, Affrime MB. Evaluation of pharmacokinetic and electrocardiographic parameters following 10 days of concomitant administration of loratadine with ketoconazoie. J Clin Pharmacol 1994; 34: 1016.